Quince Therapeutics, Inc. (IRLA) Operating cash flow 2018–2025
Quince Therapeutics, Inc. (IRLA) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$41.4MFY2025 · since FY2018: -$11.7M → -$41.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$41.4M | -29.8% |
| FY2024 | -$31.9M | -74.4% |
| FY2023 | -$18.3M | +58.5% |
| FY2022 | -$44.0M | +30.0% |
| FY2021 | -$62.9M | -23.8% |
| FY2020 | -$50.8M | -52.7% |
| FY2019 | -$33.3M | -184.5% |
| FY2018 | -$11.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More IRLA financial trends
IRLA RevenueIRLA Net incomeIRLA Net marginIRLA Gross profitIRLA Gross marginIRLA Operating incomeIRLA Operating marginIRLA Free cash flowIRLA Capital expendituresIRLA Return on equityIRLA Stock buybacksIRLA Dividends paidIRLA Total assetsIRLA Total liabilitiesIRLA Shareholders’ equityIRLA overview →